Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine
Phase 4
Completed
- Conditions
- Prevention of Meningococcal Infection
- Interventions
- Biological: Meningococcal C conjugate vaccine
- Registration Number
- NCT00310713
- Lead Sponsor
- Novartis Vaccines
- Brief Summary
Persistence of antibodies and kinetics of B cell response in healthy children after vaccination with MCC vaccine
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
- Healthy children
Exclusion Criteria
- Known hypersensitivity to any vaccine products
- Any immunodeficiency, genetic anomaly or severe acute or chronic illness
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Group 3 Meningococcal C conjugate vaccine - Group 5 Meningococcal C conjugate vaccine - Group 1 Meningococcal C conjugate vaccine - Group 4 Meningococcal C conjugate vaccine - Group 2 Meningococcal C conjugate vaccine -
- Primary Outcome Measures
Name Time Method Persistence of memory B cells in the blood at least one year after primary immunisation with MenC Vaccine at 2, 3 and 4 months of age, as determined by meningococcal C specific B-cell ELISPot assay or limiting dilution
- Secondary Outcome Measures
Name Time Method Immune Response measured 4 weeks after the booster immunisation. establish at which day CRM -197 specific B cells are detectable in the blood after booster immunisation, as determined by meningococcal C specific B-cell ELISpot assay or limiting dilution.
Trial Locations
- Locations (1)
Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road
🇬🇧Headington, Oxford, United Kingdom